TUA Symposium C: What is the consensus of Uro-oncology therapy in 2019?
2019-01-262. 5F 第三會議室
11:00 ~ 11:20Immunotherapy in urothelial carcinoma: Who will benefit?蔡育賢吳文正, 歐宴泉, 王百孚
11:20 ~ 11:40From M0 to M1 therapy of mRCC: Can immunotherapy be the first line?陳忠信吳文正, 歐宴泉, 王百孚
11:40 ~ 12:00Cytoreductive nephrectomy: Is it still necessary?虞凱傑吳文正, 歐宴泉, 王百孚